English articles
- Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King
- Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?
- ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle
- Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science
- The Next Phase of AI Drug Development: Making Molecules Survive as Drugs
- Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check
- Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital
- Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories
- RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War
- The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era
- CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease
- Drugmakers Without AI Capability May No Longer Be Called Drugmakers
- Old Targets Are Crowded, but They Can Still Make Money
- Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug
- Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena
- A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era
- Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?
- Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means
- The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal
- The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy
- Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming
- Biotech Investing Needs a Judgment System, Not More News
- Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers
- The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio
- A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track
- Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets
- Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity
- The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market
- How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow
- How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight
